Skip to main content

14-10-2020 | Gastroenterology | Video

UEGW 2020 | Treat-to-target aids ustekinumab dosing in patients with Crohn’s disease

Silvio Danese discusses the STARDUST trial looking at the benefits of a treat-to-target strategy for optimising ustekinumab treatment in Crohn’s disease based on endoscopic and clinical outcomes (3:28).

Funding for independent interviews at UEG Week Virtual 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.